NEW YORK (GenomeWeb News) – 20/20 Gene Systems said Thursday that it has licensed intellectual property related to its blood-based biomarker test for early-stage lung cancer to Johnson & Johnson subsidiary Ortho-Clinical Diagnostics.
Under the worldwide agreement, Ortho will pay 20/20 Gene Systems up-front fees, development funding, milestone payments, and royalties on product sales. 20/20 also plans to offer the test to physicians as an in-house lab service, which it hopes to launch within the next 12 to 18 months, and retained rights to enter into other licenses with a limited number of third parties.
Rockville, Md.-based 20/20 two months ago received a $150,000 investment from a joint program between Johnson & Johnson’s Corporate Office of Science and Technology and the Maryland Technology Development Corporation.
20/20 CEO Jonathan Cohen said in a statement that the goal of the collaboration is “to help establish the first accurate blood test for lung cancer that can detect the disease years earlier than the current gold standard.”
The company developed the test partly through a collaboration with researchers from the University of Kentucky, and published data related to the research in the Journal of Thoracic Oncology.